Interpretation of the Chinese Clinical Practice Guideline on the Management of Crohn's Disease (2023, Guangzhou)
-
摘要: 中华医学会消化病学分会炎症性肠病学组于2023年制定了《中国克罗恩病诊治指南(2023年·广州)》，该指南在《炎症性肠病诊断与治疗的共识意见(2018年·北京)》基础上进行了修订及更新，引入循证团队，通过严谨的制定流程，对克罗恩病的诊断、治疗、围手术期管理、合并肛周病变的管理及疾病监测进行更系统的阐述，以期提高克罗恩病的规范化诊治水平。对比2018年《共识》，主要更新的内容包括：诊断标准及高危因素的再确认、无创检测手段的应用、达标治疗理念、多种生物制剂及小分子药物的选择、更为积极的肛瘘治疗方法、强调围手术期管理策略。本文通过查阅文献，结合前沿研究动态，分析并解读2023年《指南》与2018年《共识》相比的更新之处，并探讨其在临床实践中的应用。Abstract: The Inflammatory Bowel Disease Group of the Gastroenterology Branch of the Chinese Medical Association formulated and issued the Chinese Clinical Practice Guideline on the Management of Crohn's Disease(2023, Guangzhou). This guideline has been revised and updated on the basis of the Chinese Consensus on Diagnosis and Treatment in Inflammatory Bowel Disease(2018, Beijing). Through the engagement of an evidence-based team and a strict formulation process, the guideline covers the diagnostic methods, therapeutic regime, perioperative management, treatment of perianal lesions and disease surveillance of Crohn's disease, with an aim of standardizing the diagnosis and treatment of Crohn's disease. In comparison with the 2018 Consensus, the main updated contents included: reconfirmation of diagnostic criteria and high-risk factors, the application of non-invasive methods, the notion of "treat-to-target", selection of multiple biological agents and small molecule drugs, more aggressive management for anal fistula, as well as the importance of perioperative management. Through literature research, the present review interprets the abovementioned updates by comparing the recommendations in the 2023 Guideline with the previous consensus, and finally explores its application in clinical practice.
-
Key words:
- Crohn's disease /
- diagnosis /
- treatment /
- clinical practice /
- interpretation
-
-
[1] Dolinger M, Torres J, Vermeire S. Crohn's disease[J]. Lancet, 2024, 403(10432): 1177-1191. doi: 10.1016/S0140-6736(23)02586-2
[2] Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease[J]. Gastroenterology, 2017, 152(2): 313-321. e2. doi: 10.1053/j.gastro.2016.10.020
[3] 中华医学会消化病学分会炎症性肠病学组. 炎症性肠病诊断与治疗的共识意见(2018年·北京)[J]. 中华炎性肠病杂志, 2018, 2(3): 173-190.
[4] 中华医学会消化病学分会炎症性肠病学组, 中国炎症性肠病诊疗质量控制评估中心. 中国克罗恩病诊治指南(2023年·广州)[J]. 中华消化杂志, 2024, 44(2): 100-132.
[5] Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010[J]. Inflamm Bowel Dis, 2010, 16(1): 112-124. doi: 10.1002/ibd.21048
[6] Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort[J]. Gastroenterology, 2010, 139(4): 1147-1155. doi: 10.1053/j.gastro.2010.06.070
[7] Ayling RM, Kok K. Fecal Calprotectin[J]. Adv Clin Chem, 2018, 87: 161-190.
[8] Allocca M, Kucharzik T, Rubin DT. Intestinal ultrasound in the assessment and management of inflammatory bowel disease: is it ready for standard practice?[J]. Gastroenterology, 2023, 164(6): 851-855. doi: 10.1053/j.gastro.2023.01.021
[9] Bouguen G, Levesque BG, Feagan BG, et al. Treat to target: a proposed new paradigm for the management of Crohn's disease[J]. Clin Gastroenterol Hepatol, 2015, 13(6): 1042-1050. e2. doi: 10.1016/j.cgh.2013.09.006
[10] Turner D, Ricciuto A, Lewis A, et al. International Organization for the Study of IBD. STRIDE-Ⅱ: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease(STRIDE)Initiative of the International Organization for the Study of IBD(IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD[J]. Gastroenterology, 2021, 160(5): 1570-1583. doi: 10.1053/j.gastro.2020.12.031
[11] Klenske E, Bojarski C, Waldner M, et al. Targeting mucosal healing in Crohn's disease: what the clinician needs to know[J]. Therap Adv Gastroenterol, 2019, 12: 1756284819856865.
[12] Mazzuoli S, Guglielmi FW, Antonelli E, et al. Definition and evaluation of mucosal healing in clinical practice[J]. Dig Liver Dis, 2013, 45(12): 969-977. doi: 10.1016/j.dld.2013.06.010
[13] Neurath MF, Vieth M. Different levels of healing in inflammatory bowel diseases: mucosal, histological, transmural, barrier and complete healing[J]. Gut, 2023, 72(11): 2164-2183. doi: 10.1136/gutjnl-2023-329964
[14] Ungaro RC, Aggarwal S, Topaloglu O, et al. Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease[J]. Aliment Pharmacol Ther, 2020, 51(9): 831-842. doi: 10.1111/apt.15685
[15] Buisson A, Blanco L, Manlay L, et al. Top-down versus step-up strategies to prevent postoperative recurrence in Crohn's disease[J]. Inflamm Bowel Dis, 2023, 29(2): 185-194. doi: 10.1093/ibd/izac065
[16] Eglinton TW, Barclay ML, Gearry RB, et al. The spectrum of perianal Crohn's disease in a population-based cohort[J]. Dis Colon Rectum, 2012, 55(7): 773-777. doi: 10.1097/DCR.0b013e31825228b0
[17] Thia KT, Mahadevan U, Feagan BG, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study[J]. Inflamm Bowel Dis, 2009, 15(1): 17-24. doi: 10.1002/ibd.20608
[18] Chande N, Townsend CM, Parker CE, et al. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease[J]. Cochrane Database Syst Rev, 2016, 10: CD000545.
[19] Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease[J]. N Engl J Med, 1999, 340(18): 1398-1405. doi: 10.1056/NEJM199905063401804
[20] Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease[J]. N Engl J Med, 2004, 350(9): 876-885. doi: 10.1056/NEJMoa030815
[21] Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease[J]. Gut, 2009, 58(7): 940-948. doi: 10.1136/gut.2008.159251
[22] Chapuis-Biron C, Kirchgesner J, Pariente B, et al. Ustekinumab for perianal Crohn's disease: the BioLAP multicenter study from the GETAID[J]. Am J Gastroenterol, 2020, 115(11): 1812-1820. doi: 10.14309/ajg.0000000000000810
[23] Feagan BG, Schwartz D, Danese S, et al. Efficacy of vedolizumab in fistulising Crohn's disease: exploratory analyses of data from GEMINI 2[J]. J Crohns Colitis, 2018, 12(5): 621-626. doi: 10.1093/ecco-jcc/jjy019
[24] Toh JW, Stewart P, Rickard MJ, et al. Indications and surgical options for small bowel, large bowel and perianal Crohn's disease[J]. World J Gastroenterol, 2016, 22(40): 8892-8904. doi: 10.3748/wjg.v22.i40.8892
[25] Aberra FN, Lewis JD, Hass D, et al. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients[J]. Gastroenterology, 2003, 125(2): 320-327. doi: 10.1016/S0016-5085(03)00883-7
[26] Cohen BL, Fleshner P, Kane SV, et al. Prospective cohort study to investigate the safety of preoperative tumor necrosis factor inhibitor exposure in patients with inflammatory bowel disease undergoing intra-abdominal surgery[J]. Gastroenterology, 2022, 163(1): 204-221. doi: 10.1053/j.gastro.2022.03.057
[27] Beelen EMJ, Nieboer D, Arkenbosch JHC, et al. Risk Prediction and Comparative Efficacy of Anti-TNF vs Thiopurines, for Preventing Postoperative Recurrence in Crohn's Disease: A Pooled Analysis of 6 Trials[J]. Clin Gastroenterol Hepatol, 2022, 20(12): 2741-2752. e6. doi: 10.1016/j.cgh.2021.10.021
[28] Yanai H, Kagramanova A, Knyazev O, et al. Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study[J]. J Crohns Colitis, 2022, 16(12): 1882-1892. doi: 10.1093/ecco-jcc/jjac100
-
计量
- 文章访问数: 667
- 施引文献: 0
下载: